ExpreS2ion receives 1.6 MSEK order in development program for next-generation malaria vaccine
ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that it has received a 1.6 MSEK order to perform development work as part of a Wellcome Trust funded malaria vaccine project. The project is led by Jenner Institute at the University of Oxford, and the goal is to create a next-generation blood-stage combination vaccine.The role of ExpreS[2]ion in the Wellcome Trust funded project is to contribute to the establishment of a cGMP manufacturing process of an optimised malaria antigen, RH5.2, using the ExpreS[2 ]platform. The